Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Impello Biosciences Inc. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is situated in 1 distinct art unit. The company's portfolio involves 1 distinct examiner, which provides a focused scope of interaction with the patent office for the current filings.
HAGHIGHATIAN, MINA is the busiest examiner for this portfolio, with 1 pending office action assigned. This examiner's workload accounts for the entirety of the company's current pending status. The 1 distinct examiner is the only official currently reviewing the 1 pending office action. Because there is only 1 individual assigned, the company's current prosecution experience is limited to the interactions with this official.
The 1 distinct art unit indicates that the subject matter falls within a specific technical domain of Biotechnology & Pharmaceuticals. Having 1 pending office action across 1 distinct examiner simplifies the management of the portfolio. Practitioners can focus their efforts on the specific art unit where the review is being conducted to advance the company's intellectual property goals. The 1 distinct art unit remains the sole environment for all current prosecution activity.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGHIGHATIAN, MINA | 1 | 46.0% | +39.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19016588 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | HAGHIGHATIAN, MINA | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19016588 | METHODS AND COMPOSITIONS FOR ALTERING SECONDARY METABOLITES IN PLANTS | HAGHIGHATIAN, MINA | 1616 | §102§103§112DP | Non-Final OA | — | Pending | Jan 10, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImpello Biosciences Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Mina Haghighatian has the most, with 1 of Impello Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
